Earlier this month, the Scleroderma Research Foundation hosted an international group of investigators to learn more about CONQUEST, our groundbreaking platform clinical trial, at the Systemic World Congress Meeting in Prague.
In a discussion led by CONQUEST Steering Committee Co-Chair Dinesh Khanna, MD, MSc (University of Michigan School of Medicine), the group gathered to learn more about CONQUEST’s innovative design current status, and future plans.
“This meeting was a productive step forward in growing international collaboration,” says Dr. Greg Gordon, the SRF’s Chief Medical Officer who also attended the meeting. “We gathered with a group of esteemed colleagues, and we outlined how the CONQUEST trial will accelerate current and future research into scleroderma treatments.”
SRF Board Chairman Luke Evnin, PhD worked directly with Dr. Gordon to help advance CONQUEST collaborations. “With CONQUEST, the Scleroderma Research Foundation is deepening its commitment and support for research that addresses the high unmet needs of scleroderma patients,” Luke shares.
Using a model first created over a decade ago to accelerate oncology drug development, the SRF platform clinical trial is the first of its kind in autoimmune diseases. In its initial iteration, CONQUEST will focus on Interstitial Lung Disease secondary to Scleroderma (SSc-ILD) which manifests in patients as lung fibrosis. In the future, the CONQUEST platform will be expanded to address other manifestations of scleroderma.
